Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

SCG and A*STAR to Develop better Stem Cell Manufacturing

publication date: Apr 18, 2024

Singapore’s SCG Cell Therapy and A*STAR, an official Singapore investor, will team up to build new joint laboratory research labs for cellular immunotherapies, the major focus of SCG’s portfolio. The collaboration will raise close to $22 million to develop SCG’s induced pluripotent stem cell (iPSC) technology, improving SCG’s cell therapy manufacturing as the company’s lead drug gets closer to approval. SCG101is an autologous T-cell receptor (TCR) therapy for hepatitis B virus that causes hepatocellular carcinoma, the most common form of liver cancer. The joint labs build on an existing license, research collaboration and MOU between the two groups. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital